Analysts Set INmune Bio, Inc. (NASDAQ:INMB) Target Price at $22.80

Shares of INmune Bio, Inc. (NASDAQ:INMB) have earned a consensus recommendation of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $22.80.

INMB has been the subject of several research reports. Maxim Group raised their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Rodman & Renshaw began coverage on INmune Bio in a research note on Tuesday, January 28th. They issued a “buy” rating and a $23.00 price target for the company. Scotiabank increased their price objective on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, February 11th. Finally, RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th.

INmune Bio Stock Performance

Shares of NASDAQ:INMB opened at $8.77 on Monday. INmune Bio has a 52-week low of $4.32 and a 52-week high of $12.72. The company has a market capitalization of $194.45 million, a P/E ratio of -4.02 and a beta of 1.93. The company has a 50-day simple moving average of $7.89 and a 200 day simple moving average of $6.26.

Hedge Funds Weigh In On INmune Bio

Several hedge funds and other institutional investors have recently modified their holdings of INMB. Wells Fargo & Company MN boosted its stake in INmune Bio by 51.0% in the fourth quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock valued at $30,000 after buying an additional 2,155 shares in the last quarter. Beacon Pointe Advisors LLC bought a new position in shares of INmune Bio in the fourth quarter worth about $48,000. JPMorgan Chase & Co. boosted its stake in shares of INmune Bio by 93.0% in the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock valued at $53,000 after purchasing an additional 5,461 shares in the last quarter. Two Sigma Advisers LP bought a new stake in shares of INmune Bio during the 4th quarter valued at approximately $59,000. Finally, Mariner LLC acquired a new position in INmune Bio during the 4th quarter worth approximately $65,000. Institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.